丹尼尔·奥伦多夫（Daniel Ollendorf）

Dan Ollendorf是Tufts大学医学中心评估和风险评估中心的价值测量和全球健康计划主管，以及医学助理教授。一种n internationally recognized expert in health technology assessment (HTA), Dan’s research interests include expanding the use of HTA and economic evaluation in low- and middle-income settings (particularly rapidly-growing economies), as well as refinement and use of value assessment tools in the US and other high-income settings. Prior to joining CEVR, Dan was Chief Scientific Officer at the Institute for Clinical and Economic Review (ICER) for over 10 years, where he was responsible for the conduct of systematic reviews of the comparative effectiveness of high impact health care technologies, integration of decision analysis and budgetary impact modeling into reviews of clinical evidence, engagement and collaboration with multiple stakeholders, and coordination as well as scientific oversight of the broader health technology assessment process. His 30 years of health care experience also include work in the hospital, informatics, insurance, managed care, and consulting sectors.

丹拥有博士学位阿姆斯特丹大学的临床流行病学博士学位，波士顿大学的公共卫生硕士学位和罗切斯特大学的艺术学士学位。他在主要期刊上撰写了60多种经过同行评审的文章，并广泛介绍了HTA和成本效益主题。DAN目前担任Medicare证据开发和覆盖咨询委员会（MEDCAC），国际药物经济学和成果研究协会（ISPOR）HTA理事会工作组，并且是卫生技术评估国际（HTAI）全球政策论坛的主席。